As reported in the Marketletter last week, Roche's Invirase (saquinavir) has become the second HIV protease inhibitor to be made available on the UK market after Abbott's Norvir (ritonavir), and has prompted concern over the level of funding for HIV drug treatment under the National Health Service.
At a press conference to publicize the launch, David Hawkins, consultant in HIV and genitourinary medicine at the Chelsea and Westminster Hospital, said that the UK cut funding for HIV treatment by 80% last year, and centers which deal with AIDS sufferers are currently only funded for antiretroviral monotherapy. This clearly flies in the face of many studies which have shown the benefits of giving antiretroviral drugs in combination.
The advent of new drugs such as the protease inhibitors, and the positive results of clinical trials looking at their use in combination with the older nucleoside analogs, has led to a situation in which more HIV-positive individuals are opting for drug treatment for their condition, noted Dr Hawkins. And although the epidemic in homosexuals appears to be on the decline as a result of behavioral changes, heterosexual transmission is rising, and this will increase the number of people seeking treatment still further.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze